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Abstract
Background
The bulk of randomized trial evidence for the expanding use of High Flux (HF) hemodialysis
worldwide comes from two randomized controlled trials, one of which (HEMODIALYSIS,
HEMO) allowed, while the other (Membrane Outcomes Permeability, MPO) excluded, the
reuse of membranes. It is not known whether dialyzer reuse has a differential impact on out-
comes with HF vs low flyx (LF) dialyzers.
Methods
Proportional Hazards Models and Joint Models for longitudinal measures and survival out-
comes were used in HEMO to analyze the relationship between β2-microglobulin (β2M)
concentration, flux, and reuse. Meta-analysis and regression techniques were used to syn-
thesize the evidence for HF dialysis from HEMO and MPO.
Findings
In HEMO, minimally reused (< 6 times) HF dialyzers were associated with a hazard ratio
(HR) of 0.67 (95% confidence interval, 95%CI: 0.48–0.92, p = 0.015), 0.64 (95%CI: 0.44 –
0.95, p = 0.03), 0.61 (95%CI: 0.41 – 0.90, p = 0.012), 0.53 (95%CI: 0.28 – 1.02, p = 0.057)
relative to minimally reused LF ones for all cause, cardiovascular, cardiac and infectious
mortality respectively. These relationships reversed for extensively reused membranes (p
for interaction between reuse and flux < 0.001, p = 0.005) for death from all cause and car-
diovascular causes, while similar trends were noted for cardiac and infectious mortality (p of
interaction between reuse and flux of 0.10 and 0.08 respectively). Reduction of β2M ex-
plained only 1/3 of the effect of minimally reused HF dialyzers on all cause mortality, while
non-β2M related factors explained the apparent attenuation of the benefit with more exten-
sively reused dialyzers. Meta-regression of HEMO and MPO estimated an adjusted HR of
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0.63 (95% CI: 0.51–0.78) for non-reused HF dialyzers compared with non-reused LF
membranes.
Conclusions
This secondary analysis and synthesis of two large hemodialysis trials supports the wide-
spread use of HF dialyzers in clinical hemodialysis over the last decade. A mechanistic un-
derstanding of the effects of HF dialysis and the reuse process on dialyzers may suggest
novel biomarkers for uremic toxicity and may accelerate membrane technology innovations
that will improve patient outcomes.
Introduction
Patients with end-stage renal disease (ESRD) undergoing maintenance hemodialysis (HD)
have a high mortality rate despite continuous improvements in technology and dialytic care
[1]. Worldwide 60% of patients are dialyzed with High Flux (HF) dialyzers. These dialyzers fa-
cilitate the removal of toxins larger than urea [2], based on observational and epidemiologic
studies [3–7] suggesting a clinical benefit from their use. Nevertheless, a Cochrane meta-analy-
sis of ten randomized controlled trials (RCTs) on 2915 patients has shown a benefit of HF
dialysis on cardiovascular mortality but not on all-cause mortality [8]. In this meta-analysis,
the majority of patients (85%), events (96.5%) and thus, the overwhelming evidential weight
(96.1%) for or against the benefits of HF dialysis comes from two RCTs; i.e. HEMODIALYSIS,
(HEMO) [8] and the Membrane Permeability Outcome, (MPO) [9]; which yielded numerically
different estimates for the effect of HF membranes on survival.
Dialyzer reuse, was permitted only in HEMO [9,10] and is considered a key interventional
difference between the two RCTs of HF dialysis [11,12]. Therefore reuse has been offered as
one potential explanation for the somewhat divergent findings of these two studies. Neverthe-
less, an assessment of the impact of reuse on outcomes of HF dialysis in HEMO has not been
performed to date. Such an assessment may inform technology use decisions worldwide, as HF
membranes are the de-facto dialysis industry standard. Reuse of HF membranes is still prac-
ticed in the US [13] and is widely employed in resource limited settings [14,15] providing a jus-
tification for revisiting the effects of reuse on outcomes in HEMO
The major objective of this work is to explore the associations of non-reused and minimally
reused HF v.s. LF dialyzers in the context of HEMO andMPO. Secondarily we were interested to
assess these effects in the medically important subgroups of patients with hypo-albuminemia or
diabetes.To describe the relative role of β2-microglobulin (β2M) concentration, membrane flux
and reuse on patient outcomes in HEMO, we supplemented conventional survival analyses with
emerging techniques for the simultaneous (joint) modeling of patient level biomarkers and sur-
vival. Meta-regression techniques were used to assess the impact of non-reused HF dialyzers
simultaneously considering the evidence in both HEMO andMPO. Finally, we undertook simu-
lations of patient survival under various scenarios of reuse and adoption of HF dialysis.
Subjects and Methods
Subjects and Data
We used the patient level data from the HEMO RCT of the effects of HD dose and membrane
flux [16] as distributed by the National Institute of Diabetes and Digestive and Kidney Diseases
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(NIDDK). Data are available from the NIDDK repository website http://www.niddkrepository.
org. We classified HEMO participants into cohorts of increasing reuse, based on monthly col-
lected dialysis information. Patients were assigned to the most commonly observed reuse
method in their study records since the same reuse technique was utilized in over 92% of the
sessions for the vast majority (85%) of the study patients. Patients were classified as dialyzed
with non-reused membranes, if the number of reuses for their dialyzer was zero for every
monthly dialysis session in the study records. We used a two-step procedure to classify all
other patients to cohorts of increasing dialyzer reuse. At the first step we computed the 97.5th
quartile for the number of reuses for each study participant during the entire study period. Sub-
sequently, these individual measures of reuse exposure were grouped into quartiles. In addi-
tion, the cumulative mean number of filter reuses was computed on a monthly basis for each
patient and was used for sensitivity analyses in survival and Joint Models. We carried out this
sensitivity analysis to ensure that the results were robust to our approach of assigning reuse.
β2M clearance was calculated with a variable-volume single-pool model, adjusted for the fluid
removal during dialysis [17,18].
The Institutional Review Board (IRB) of the University of New Mexico approved this sec-
ondary analysis of the HEMO Randomized Controlled Trial (Study ID 13–468 decision of 12/
12/2013). All study participants had provided informed consent to participate in HEMO, and
the ethics committees/IRBs of participating centers had reviewed and approved the consent
form during protocol review. These documents and the HEMO can be downloaded from the
NIDDK repository. Individual HEMO participants were not consented for this secondary anal-
ysis, because the data as distributed by the NIDDK has been de-identified. Furthermore the
data use agreement between the investigators of this paper and NIDDK prohibits us from mak-
ing any contact to identify individuals, families or communities. The IRB of the University of
New Mexico waived the requirement for an informed consent for this secondary analysis after
reviewing the original consent form that HEMO participants signed upon their enrollment, the
data use agreement between the investigators and NIDDK and the associated research protocol
submitted to the NIDDK.
Statistical Methods
Survival Modeling. We applied the proportional hazard (Cox) model to compute hazard
ratios (HRs) in patient cohorts. These models were adjusted for all baseline covariates used in
the initial trial report: Kt/V arm assignment, age, gender, presence of diabetes, race, co-morbid-
ity score (ICED), duration of ESRD, serum albumin level, dialysis dose (Kt/V arm assignment)
and flux. We also adjusted survival models for vascular access and residual urine output in
order to minimize residual confounding from omitting these prognostically important vari-
ables. The role of dialysis access is well established as a predictor of survival in the nephrology
literature (e.g. in the USRDS US registry[19], the Renal Disease Registry in Ontario[20] and
the international comparisons in the DOPPS registry[21]). We have previously found access to
be a confounder in statistical analysis of the CHOICE prospective dialysis cohort in the US
[22], while more recently access was found to modify the risk associated with dialysis in for-
profit v.s. non-for-profit dialysis units in the US[23]. Residual renal function (RRF) has been
found to be a predictor of survival in studies from the Netherlands (NECOSAD-2)[24], in the
US[25] and even in the context of incremental dialysis[26]. It is a topic of re-emerging impor-
tance in the dialysis literature (see [27]for an excellent review). To account for clustering of di-
alysis patients in units, we computed robust (sandwich) standard error estimates in all Cox
models. This methodology[28], has been become the de facto standard for analyzing hemodial-
ysis outcomes (see[29–33] for indicative, non-exhaustive list of references) since its initial
Dialyzer Reuse and High Flux Dialysis
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introduction. Patient’s follow-up time was censored if they were alive at the end of the study or
when they received a kidney transplant, but not when they dropped out from the study in ac-
cordance with the HEMO statistical analysis plan [9].
Repeated Measures Modeling. We related β2M clearance to the extent of reuse with
mixed effect models that employed a nested, individual-within-center random effect structure
for the correlation between repeated measures obtained in the same individual. Generalized Es-
timating Equations (GEEs) for binary outcomes were used to analyze the membrane material
(polysulfone vs. non-polysulfone). The use of the two different repeated measures methodolo-
gies is justified by the design of the HEMO study and our research questions. In particular, the
HEMO protocol tracked clearance of beta 2 microglobulin at the patient level. Therefore to an-
alyze the relevant variables (beta 2 microglobulin and clearance) an individual level approach
such as a (generalized) linear mixed model is indicated. On the other hand, HEMO did not en-
force the use of specific membrane materials on a patient or a study center level, so that analyz-
ing the population exposures becomes the relevant question. GEEs implement population level
models, and are the appropriate methodology to use for our research question[34].
Joint Modeling of predialysis β2M concentration, and survival. We characterized the re-
lationship between flux, β2M concentration, and survival using a joint model (JM) [35] for re-
peated measures and survival. A JM is an analytical method for the simultaneous estimation of
treatment effects on survival outcomes, the effects of treatment on the concentration of a bio-
marker over time (trajectory function) and the independent effects of the latter on survival.
Since other factors may affect survival either directly or indirectly (through the biomarker con-
centration) the JM may adjust for them to reduce residual confounding. The JM overcomes the
biases implied by the simplistic inclusion of time updated values of biomarkers in survival
models. These biases which arise from measurement error and informative censoring (e.g. lack
of measurements after patient’s death) may seriously compromise the inferences of the survival
models[36,37]. The interpretation of the fitted joint model assigns direct treatment effects (not
associated with changes in the biomarker i.e. β2M trajectory and indirect treatment effects (as-
sociated with changes in the biomarker concentration and the effects of the latter on survival).
The overall treatment effect (measured in the log-hazard scale) is the sum of the direct and in-
direct effects (Fig 1) [38–40] and is usually not different from the one estimated by the Cox
model.
To describe the trajectory of β2M over time in HEMO we used a natural cubic spline with
internal knots at 45 and 90 days and two external knots at 0 days (beginning of the study) and
6 months after randomization. The adopted specification allowed flexible modeling of a) the
non-linear changes in β2M concentration, resulting from changing membrane flux in the six
months post-randomization, followed by a b) linear trend afterwards. The justification for this
bi-phasic model was based on previous clinical investigations [41–45] and computer simula-
tions [46–48], demonstrating that changes in serum β2M concentration occur within a few
weeks after abrupt changes in dialytic clearance with very little change thereafter. As patients
in HEMO could be dialyzed either with LF or HF before randomization, we allowed the trajec-
tory of β2M concentration to differ according to both pre-randomization and post-randomiza-
tion membrane flux. Hence our model anticipated increases or decreases in β2M concentration
(e.g. patients switching from HF to LF membranes and vice versa) and stable β2M trajectories
(e.g. patients who were randomly assigned to the same flux as the filters used prior to study
enrollment).
The selection of the position of the internal knots was motivated by the sampling frequency
of predialysis β2M concentration in HEMO: β2M was measured on the first and second month
and then every other month (HF arm) and at months 1, 4 and yearly thereafter (LF arm).
Hence, we specified the position of the internal knots to ensure that sufficient data points were
Dialyzer Reuse and High Flux Dialysis
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available at each interval (0–45 days, 45–90 days, 90–180 days and 180 days-end of follow up)
for the estimation of the spline coefficients. Of note, only a small number of HEMO study par-
ticipants (<10%) had β2M determinations at baseline and these measurements were included
in the dataset that was supplied to the JM.
We utilized the capability of JMs to yield dynamic, subject specific survival probabilities
from a baseline set of measurements [31] in order to predict the expected outcomes (difference
in 5 year survival probability) under all possible flux and reuse combinations that were utilized
in HEMO (S1 Text: Simulations). These simulations allow us to predict the effects of reusing ei-
ther LF or HF dialyzers in a cohort of patients with similar characteristics to the HEMO study
participants. These are Bayesian probability estimates which do not admit a conventional p-
value calculation for their comparison. Hence, we adopted the literature convention, and con-
sidered differences in survival as “significant” if the corresponding 95% Credible Interval (CrI,
Fig 1. Conceptual depiction of the Joint Modeling Framework. A joint model is an analytical method for the simultaneous estimation of treatment effects
on survival outcomes, the effects of treatment on the concentration of a biomarker over time (trajectory function) and the effects of the latter on survival. As
the true biomarker level is unobserved, a JM has to reconstruct its trajectory before these effects can be estimated. Other factors may affect survival either
directly or indirectly (through the biomarker concentration) and they can be used to adjust a JM and thus reduce residual confounding. One possible
interpretation of the fitted joint model effects on survival assigns direct treatment effects (not associated with changes in the biomarker trajectory, α) and
indirect treatment effects (associated with changes in the biomarker concentration, given by the product of β and γ). Hence, the overall treatment effect in the
Hazard Ratio scale is the (exponentiated) sum of direct and indirect effects. This effect is usually numerically similar to the one estimated by a Cox model.
doi:10.1371/journal.pone.0129575.g001
Dialyzer Reuse and High Flux Dialysis
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the range of values in which 95% of the probability is contained) excludes zero. Further techni-
cal details about the JM are given in S1 Text.
Evidence Synthesis of HEMO and MPO. HEMO and MPO are the largest prospective
RCTs of membrane flux, accounting for>96% of the total weight of evidence in a recent
Cochrane Group Systematic Review of the impact of HF dialyzers on outcomes [8]. The afore-
mentioned meta-analysis did not account for differences in reuse, patient demographics, dialy-
sis dose or statistical adjustments for baseline patient characteristics that were employed in
HEMO and MPO (S1 Text). To account for the differences in interventions, patients in HEMO
were cross-classified according to the single-pool Kt/V (spKt/V) arm(coded as standard or
high), flux and quartiles of reuse, before computing discrete outcomes (number of events and
patient years) for unadjusted meta-analyses. Since the average dialysis dose employed in MPO
was similar to the standard dose employed in HEMO, all patients fromMPO were classified as
receiving standard dialysis with either LF or HF membranes. To align the statistical models
used in the trials, we re-analyzed survival in HEMO using the same statistical model that the
MPO investigators used in their report. Investigators in MPO, adjusted the hazard ratio of flux
for age, Kt/V, gender, diabetes, comorbidity score and type of access. This information was ex-
tracted from the MPO publication (Table 4 in [19]). We applied the same model in HEMO to
yield adjusted estimates for high flux dialysis within each of the eight cohorts defined on the
basis of reuse quartile and Kt/V assignment. To combine the adjusted hazard ratios from both
studies, we utilized random effects meta-regression. Meta-regression adjusted these flux esti-
mates for spKt/V and the average reuse number of the patients in each HEMO reuse quartile.
As dialyzers were not reused in MPO, the corresponding reuse number was set to zero.
We also undertook subgroup analysis in hypoalbuminemic patients (a prespecified sub-
group in the MPO analytic protocol). Secondary analyses of the MPO and other observational
datasets [6] suggest that diabetic patients may derive an additional benefit from HF dialysis.
Consequently, we also considered a subgroup analysis of the diabetic study participants in the
two studies. Further technical details about the meta-analysis are given in Supplementary
Methods (S1 Text, Section: “Meta-analysis and Meta-regression of HEMO and MPO”).
All statistical analyses were performed with R versions 2.9.2–2.15.1; joint modeling was un-
dertaken with the R package “JM” version 1.0–1.1 [34,35].
Results
Patients and Reuse Exposures
Characteristics of patients were similar across quartiles of reuse with the exception of patients
of white race and female gender who were more likely to be represented in the lowest reuse
quartile (Table 1). As a group, patients at the lowest reuse quartile were also more likely to be
enrolled later in the trial, to be dialyzed with HF dialyzers before randomization and to have re-
sidual urine output (Table 1). However, within reuse quartiles there were no substantial differ-
ences in characteristics in patients randomized to LF versus HF membranes (S1–S4 Tables).
There was no statistically significant difference in the odds of using polysulfone vs. non-poly-
sulfone dialyzers between the two flux arms in the first (Odds Ratio (OR): 0.88, 95%CI: 0.60–
1.27), p = 0.48) and across the remaining reuse quartiles (p for the interaction between flux and
2nd -4th quartiles: 0.21, 0.66, 0.27). The most common reuse method involved peracetic acid
(PAA, 45.3% of patients), followed by formaldehyde (FAH, 25.1%), gluteraldehyde (GAH,
10.7%) and heated citric acid (HCA, 9.4%); only a minority (9.5%) of all HEMO patients were
dialyzed with non-reused filters.
The method (S5 Table) and extent of reuse differed among different dialyzers, ranging from
10.9 ± 5.6 (PAA) to 15.2 ± 5.0 (FAH) times in accordance with the labeling information of the
Dialyzer Reuse and High Flux Dialysis
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dialyzers and dialysis center practices. Mixed model analysis demonstrated wide differences in
the average clearance of reused HF dialyzers by reuse method: 2.72±1.13 ml/min (FAH,
p = 0.016), -1.26±1.31 ml/min (GAH, p = 0.33), 5.71±1.35 ml/min (HCA, p<0.001), -12.9±1.1
ml/min (PAA, p<0.001), relative to non-reused ones (38.4±0.97 ml/min).
The average predialysis β2M concentration in patients dialyzing with non-reused HF mem-
branes was 31.1 ± 0.99 mg/l; β2M was non-significantly increased by FHA, GAH or HCA re-
processing: 1.57 ± 1.15 mg/l (p = 0.17), 1.59 ± 1.39 mg/l (p = 0.23), 1.54 ± 1.40 mg/l (p = 0.27)
respectively. Only reprocessing with PAA was associated with a moderately higher β2M
Table 1. Baseline Characteristics of HEMO Participants by Reuse Quartile.
Reuse Quartile p
N 531 443 448 404
Range of Number of Reuses 0–6 7–12 13–17 >17
Flux Assignment 0.59
High Flux 48% (254) 48% (213) 52% (234) 52% (209)
Kt/V Assignment 0.27
High Kt/V 50% (268) 53%(236) 48%(216) 47%(190)
Prerandomization Membrane Flux <0.001
High Flux 47% (246) 66% (289) 59% (264) 72% (289)
Age 58 ± 14 58 ± 14 58 ± 13 57 ± 15 0.90
Race <0.001
Black 56% (300) 72% (321) 62% (279) 60% (244)
Diabetic Status 0.52
Diabetic 44% (234) 46% (205) 46% (207) 42% (169)
Gender 0.33
Female 59% (312) 56% (248) 53% (237) 56% (228) 0.045
Duration (years) 3.43 ± 4.17 3.86 ± 4.44 4.06 ± 4.75 3.71 ± 4.05 0.56
Cause of ESRD
Glomerulonephritis 15% (79) 15% (66) 13% (60) 12% (47)
Hypertension 28% (150) 32% (140) 32% (143) 36% (146)
Diabetes 37% (199) 38% (167) 39% (176) 34% (139)
Ischemic Nephropathy 7% (37) 5% (21) 6% (25) 4% (18)
Acute Renal Disease 4% (22) 3% (12) 1% (6) 2% (10)
Other 9% (44) 7% (37) 9% (38) 12% (44)
Albumin (g/dl) 3.61 ± 0.35 3.63 ± 0.35 3.63 ± 0.37 3.63 ± 0.36 0.66
Residual Renal Function* 0.007
Urine Volume (>200 ml/day) 17% (90) 9% (41) 14% (63) 13% (54)
ICED 1.93 ± 0.84 1.98 ± 0.83 1.93 ± 0.83 2.06 ± 0.82 0.085
Vascular Access
Arteriovenous Fistula 35% (188) 33% (148) 34% (151) 31% (126) 0.27
Arteriovenous Graft 57% (305) 58% (258) 61% (274) 61% (247)
Catheter/Other 7% (38) 8% (37) 5% (23) 7% (31)
Year of Randomization(since the beginning of HEMO) 3.19 ± 1.65 1.69 ± 1.41 1.62 ± 1.53 1.92 ± 1.68 <0.001
Summary statistics are presented as mean ± standard deviation and as % (frequencies) for continuous and categorical variables respectively. Tests used
to compare variables Pearson test (categorical), Kruskal-Wallis (continuous). The total number of patients (1826) differs from the number of patients
enrolled in HEMO, because there was no available information about reuse for 20 subjects who died before their ﬁrst post-enrolment evaluation. ICED:
Index of Coexistent Diseases.
doi:10.1371/journal.pone.0129575.t001
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concentration of 4.03 β2M ± 1.08 mg/l (p<0.001) relative to non-reused HF dialysis in these
unadjusted analyses. After adjusting for a large number of covariates (Kt/V, race, gender, dia-
betes, comorbidity score, duration of dialysis dependency, vascular access, transplantation
status, smoking, BMI, albumin, urine output (as more or less than a cup per day) and study
center, reuse with PAA was not associated with higher β2M concentration (difference of
-0.28 ± 1.65, p = 0.87).
In summary, the potentially large impact of reuse method on β2M clearance did not trans-
late into a substantial effect on predialysis β2M concentration. As the HEMO study protocol
controlled the maximum number of reuses, according to the effects of reuse protocol on clear-
ance, the average β2M clearance did not materially differ across reuse quartiles (Fig 2).
Relative effect of HF dialysis on survival depends on the extent of
dialyzer reuse
The effects of HF dialysis were modified by the extent of dialyzer reuse. In adjusted Cox models
(S6 Table), the interaction between flux and reuse was statistically significant for all-cause
(p<0.001) and cardiovascular (p = 0.005) mortality. A trend for higher relative mortality for
cardiac and infectious causes (p = 0.10 and p = 0.08 for the interaction between HF and reuse)
was also noticed. These statistical interactions imply that a beneficial effect of HF relative to LF
dialysis on all-cause and cause-specific mortality was attenuated for patients dialyzed with fil-
ters that were reused more than 6 times (Table 2). Sensitivity analyses, which used the time up-
dated (cumulative mean) number or reuses did not yield substantially different HR estimates
(S7 Table). In analyses adjusting for reuse method, the interaction between flux and extent of
reuse remained significant. In these analyses, FAH and GAH were associated with numerically
worse relative outcomes to other reuse methods (not shown). There was no interaction
Fig 2. Distribution of predicted β2M clearance across quartiles of membrane reuse in HEMO.
Controlling the extent of reuse by the HEMO study protocol yielded average clearances that were equivalent
across reuse quartiles in patients receiving HF dialysis. Average β2M clearance by HF dialyzers in the 2nd to
4th reuse quartile, was 1.26±1.02 (p = 0.21), 1.47±1.00 (p = 0.14) and 5.41±1.03 (p<0.001) ml/min higher
relative to the first quartile (31.8±0.69 ml/min).
doi:10.1371/journal.pone.0129575.g002
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between reuse, baseline urine production and dialysis flux (p for all three way interactions>
0.77) suggesting that the effects of reuse and flux did not differ between anuric patients and
those with minimal RRF.
When interactions between albumin concentration at baseline and HF dialysis were exam-
ined, we noted a statistically significant effect for cardiac (p = 0.009), and a trend for cardiovas-
cular and all-cause mortality (p = 0.051 and p = 0.096 respectively). The direction of the
interaction term indicates a larger benefit of HF dialysis for patients with lower albumin levels.
No interaction was noted between the presence of diabetes at baseline and all-cause or cause
specific mortality (p>0.20 for all interactions).
To better understand these findings we undertook a number of joint modeling analyses aim-
ing to ascertain whether reuse a) affected the exposure to middle molecules (β2M concentra-
tion) b) whether the association of a given β2M concentration with survival differed according
to the extent of dialyzer reuse and c) whether the apparent attenuation of the protective effect
of HF dialysis reflected worse outcomes with reused high flux membranes or improved survival
in patients exposed to reused LF dialyzers.
The effects of reuse on outcomes of HF dialysis are not related to middle
molecules
Dialyzer reuse is not associated with differential changes in β2M concentration. In the
first six months of HEMO, β2M increased in patients assigned to LF membranes and decreased
in patients assigned to the HF arm (Table 3, acute slope); the rate of change of β2M was smaller
after the first six months (Table 3, chronic slope). The rate of accumulation of β2M in patients
exposed to reused LF membranes was smaller by 1.01 to 2.01 mg/l/year compared to the non-
reused membranes. Rates of accumulation of β2M did not differ between HF and LF mem-
branes subjected to the same extent of reuse (p: 011–0.98 Table 3). Differences in the concen-
tration of β2M between the HF and LF arms were established early and maintained throughout
the duration of the study (Fig 3). Adjusted mean differences (SE) in predialysis β2M concentra-
tion between LF and HF dialysis were not materially different in the various reuse quartiles:
-8.29(0.99), -9.68(1.22), -6.73(1.06), -8.42(1.27) mg/dl for 0–6, 7–12, 12–17,>17 reuses
respectively.
Changes in β2M account only partly for the effects of non-reused HF dialyzers. In joint
models, serum β2M concentration was a statistically significant predictor of survival: each 10
mg/L elevation was associated with an estimated HR of 1.16 (95% CI: 1.07–1.25, p<0.001). In-
direct effects of HF vs. LF dialysis (i.e. those associated with changes in serum β2M) were not
Table 2. Hazard Ratio of Death for All Cause and Cause Specific mortality between High Flux and Low Flux Dialysis versus extent of Reuse.
1st Quartile (N = 526) 2nd Quartile (N = 436) 3rd Quartile (N = 438) 4th Quartile (N = 403)
Number of Reuses 0–6 6–12 12–17 >17
All Cause Mortality 0.67 (0.48–0.92) p = 0.015 0.86 (0.66–1.12) p = 0.27 0.86 (0.64–1.14) p = 0.29 1.45 (1.13–1.86) p = 0.003
Cardiac Mortality 0.64 (0.44–0.95) p = 0.03 0.69 (0.44–1.08) p = 0.10 0.83 (0.55–1.26) p = 0.37 0.98 (0.68–1.41) p = 0.91
Cardiovascular Mortality 0.61 (0.41–0.90) p = 0.012 0.62 (0.40–0.95) p = 0.029 0.81 (0.55–1.20) p = 0.30 1.16 (0.88–1.54) p = 0.29
Infectious Mortality 0.53 (0.28–1.02) p = 0.057 1.11 (0.69–1.81) p = 0.66 0.64 (0.35–1.18) p = 0.16 1.30 (0.85–1.99) p = 0.22
Hazard Ratio (HR) estimates were obtained from a Cox regression model adjusting for reuse quartile, ﬂux and Kt/V assignments, age, sex, diabetes,
duration of ESRD dependency (upon study enrolment), ICED, albumin, vascular access, pre-randomization ﬂux, residual urine volume, and ﬁnally the
interaction between reuse quartile and ﬂux; the baseline hazard was stratiﬁed by study centre. Reported Relative Risks are model predictions and
associated 95% CI for patients dialyzed with high ﬂux relative to patients dialyzed with low ﬂux, reused to the same extent as the former. Results based on
1803 patients with complete data for model ﬁtting.
doi:10.1371/journal.pone.0129575.t002
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different across reuse quartiles (Table 4) and were moderate in magnitude (hazard ratios rang-
ing from 0.87–0.91). On the other hand, direct effects, i.e. not explained by changes in predialy-
sis β2M, differed across reuse quartiles and in fact reversed direction for highly reused
membranes (Table 4). Total effects of flux were nearly identical to the results of the Cox models
in Table 2 (not shown).
Similar findings were obtained when reuse was treated as a time updated variable in sensi-
tivity analyses: the best fitting JM suggested a quadratic relationship between the direct and
total effects of flux and HR of death so that the hazard ratio was increased in patients receiving
HF dialysis when these dialyzers were reused more than 17 times (S1 Fig). In sensitivity analy-
ses, the attained β2M concentration did not have a differential association with survival in pa-
tients treated with reused HF dialyzers (p for the interaction between indirect effect and flux,
indirect effect and cumulative reuse and flux by cumulative reuse: 0.28, 0.10 and 0.25
respectively).
Reuse is not associated with worse outcomes in HF dialysis, but improves outcomes in
patients exposed to LF membranes. We used JMs to predict absolute survival in a cohort of
simulated patients who were exposed to the 8 different combinations of flux and quartiles of
reuse. Irrespective of the extent of their reuse, HF membranes are predicted to confer a survival
advantage over minimally reused LF dialyzers, e.g. a 9.9% increase in 5 year survival (95% CrI:
1.6%-18.0%) and 9.2% (95% CrI: 1.3–19.4%) for the lowest and highest reuse quartiles respec-
tively. However, compared to minimal reuse of HF dialyzers, extensive reuse of these mem-
branes was not associated with worsening survival, i.e a difference in five year survival
probability of -0.7% (95% CrI -10.5% to 6.2% for the highest reuse quartile vs. minimal reuse).
The neutral effect of reuse on outcomes of HF dialysis was also evident in the Kaplan Meier
Table 3. Average Acute (first six months) and Chronic Slopes (> 6 months) of Predialysis β2M Concentration according to Reuse Quartile and
Membrane Flux.
Acute Slope (0–6 months) Chronic Slope (>6 months)
Reuse Estimate (SE) Pǂ P* Estimate (SE) Pǂ P*
Low Flux
0–6 6.61 (1.77) Ref Ref 2.27 (0.37) Ref Ref
7–12 -1.49 (2.71) 0.58 Ref -1.56 (0.49) 0.002 Ref
13–17 1.50 (2.65) 0.57 Ref -2.01 (0.49) <0.001 Ref
>17 0.46 (2.94) 0.89 Ref -1.07 (0.50) 0.003 Ref
High Flux
0–6 -5.44 (1.77) Ref <0.001 1.54 (0.28) Ref 0.11
7–12 4.66 (2.67) 0.081 0.004 -0.51 (0.38) 0.17 0.49
13–17 5.00 (2.52) 0.047 0.001 -1.26 (0.37) <0.001 0.98
>17 5.06 (2.85) 0.076 0.021 -0.45 (0.43) 0.28 0.78
Estimates of slopes are given in Δmg/L β2M/year relative to the ﬁrst quartile of reuse in each ﬂux arm (entry in rows labelled “0–6”); all estimates were
obtained by a joint model for the (untransformed) β2M concentration and survival. The longitudinal and survival submodels adjusted for reuse quartile, ﬂux
and Kt/V assignments, age, sex, diabetes, duration of ESRD dependency (upon study enrolment), ICED, albumin, vascular access, pre-randomization
ﬂux, residual urine volume, study center and the interaction between reuse quartile by ﬂux. To model the changing trajectories of β2M as a result of
patients being assigned to dialyzers with a different ﬂux than the one used before randomization, the longitudinal component also included interactions
between pre- and post-randomization ﬂux and a spline function of time since randomization. The baseline hazard of the survival submodel was modeled
with a natural spline with two internal knots at 45 and 90 days and two boundary (external) knots at 0 and 180 days.
ǂP-values comparing each slope to the reference category within each ﬂux arm * P value comparing the slope between the same reuse category of the
two ﬂux arms.
doi:10.1371/journal.pone.0129575.t003
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Fig 3. Predicted predialysis β2M concentrations across reuse quartiles andmembrane flux in HEMO participants. These predictions were obtained
by fitting a Joint Model to the HEMO dataset which was then used to predict the β2M concentration for the HEMO study participants at different time points.
The panels show the mean and standard deviation obtained by averaging individual level predictions at each time point. Separation between the high (HF)
and the low flux(LF) arms in terms of the β2M concentration were established early in the trial. There was very little difference in the separation of flux arms
across the quartiles of reuse, i.e. estimated difference (SE) in β2M concentration between HF and LF was -8.27 (0.56), -9.67 (1.22), -6.72 (1.06), and -8.42
(1.26) mg/L in the 1st-4th reuse quartiles respectively.
doi:10.1371/journal.pone.0129575.g003
Table 4. Joint Model estimates of Adjusted Hazard Ratios for All Cause Mortality associated with the use of High Flux vs. Low Flux Dialyzers under
different extents of Reuse.
Indirect Effect Direct Effect
Reuse Estimate 95% CI P Estimate 95% CI P
0–6 0.89 0.82–0.95 <0.001 0.78 0.57–1.06 0.12
7–12 0.87 0.80–0.93 <0.001 0.98 0.75–1.28 0.88
13–17 0.91 0.85–0.96 <0.001 0.98 0.75–1.28 0.87
>17 0.88 0.82–0.95 <0.001 1.72 1.28–2.32 <0.001
Hazard Ratio (HR) estimates were obtained from a Joint Model for pre-dialysis β2M (untransformed) and all cause-mortality as detailed in the methods
and the legend of Table 3. Reported Hazard Ratios and associated 95% CI for patients dialyzed with HF are relative to patients dialyzed with LF ones,
reused to the same extent as the HF ones.
doi:10.1371/journal.pone.0129575.t004
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curves which were nearly superimposable (Fig 4). On the other hand, reuse of LF membranes
modified survival (Fig 4) especially; the highest five year survival probability was noted for the
most extensively reused LF dialyzers: 55.6% (95% CrI: 49.3–61.4%).
From a comparative effectiveness perspective, these simulations imply that the effects of HF
dialysis in a given reuse setting would depend on the extent of the reuse and the referent (LF vs.
HF). In HEMO, reuse of low flux dialyzers was associated with improved absolute clinical out-
comes in the LF arm, but was not associated with either worse or improved outcomes in the
HF arm. These patterns underlie the apparent attenuation of the hazard ratio of high flux dialy-
sis with reuse (Table 2)
Synthesis of HEMO and MPO results suggests a benefit for non-reused/minimally re-
used HF dialyzers that may be larger in hypoalbuminemic patients. When synthesizing the
evidence from the adjusted analyses of HEMO and MPO without accounting for the extent of
reuse or small molecule clearance, we obtained results compatible with the ones reported in the
unadjusted meta-analysis by the Cochrane group [8]: HR for all cause mortality of 0.89, 95%
CI (0.71–1.11, p = 0.28, S2 Fig panel A) vs. 0.95 (95% CI: 0.87–1.04, p = 0.23[32]). In meta-
analysis of adjusted HRs, HF dialysis was associated with a statistically significant effect in the
subgroup of hypoalbuminemic patients (HR: 0.70, 95%CI: 0.52–0.93, p = 0.013, S2 Fig, panel
B) but not those with diabetes (HR: 0.87, 95%CI: 0.68–1.11, p = 0.26, S2 Fig, panel C).
In meta-regression analyses, both linear and quadratic relationships between flux and num-
ber of reuses were examined, with the later providing better fit to the data (S1 Text: Supple-
mentary Results). Model predictions for the HR of HF dialysis for different number of reuses
and standard Kt/V dialysis dose are shown in Fig 5; the model predicts an adjusted HR of 0.63
(95% CI: 0.51–0.78) for HF dialysis with non-reused membranes, with the relative effects of
flux progressively weaning after the 7th reuse. When we examined outcomes in patients with
hypo-albuminemia and in diabetics we obtained similar results: a model predicted HR of 0.56,
Fig 4. Predicted survival curves obtained by dynamic simulations of Joint Models. These were derived
by counterfactually exposing HEMO study participants to all possible flux and reuse combinations. Individual
survival probability curves were averaged at each observation point and these population averaged curves
are depicted separately for low flux(LF) and high flux(HF) dialysis. Five year survival probabilities (P5,
estimate and 95%Credible Interval) were as follows: 33.8% (28.0%-39.4%), 36.1% (30.8%-41.0%), 42.4%
(36.9%-47.8%) and 55.6% (49.3%-55.8%) for increasing reuse of LF membranes. P5 (estimates and 95%
Credible Intervals) for increasing reuse of HF dialyzers were: 43.7% (37.4%-49.1%), 38.% (32.9%-43.5%),
44.8% (38.1%-50.7%) and 43.0% (37.0%-49.1%).
doi:10.1371/journal.pone.0129575.g004
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(95% CI: 0.36–0.86, p = 0.009) and HR of 0.64 (95% CI: 0.46–0.89, p = 0.008) respectively asso-
ciated with HF dialysis with non-reused dialyzers (graphs not shown). When we considered
only the HEMO participants dialyzed with non-reused membranes, the results were consistent
with the meta-regressions in showing a protective effect of HF dialysis that was numerically
higher in hypo-albuminemic and diabetic patients (Fig 6).
Discussion
In this secondary analysis of HEMO we found that minimally reused HF filters were associated
with reduction in the hazard ratio for all-cause and cause-specific mortality relative to their LF
counterparts, but this relation reversed at high levels of reuse. In joint modeling analyses of sur-
vival and predialysis β2M levels we found that this mortality pattern was not associated with
differential effects on β2M concentration by reused dialyzers i.e. an indirect effect of flux. Evi-
dence synthesis of the HEMO and MPO, the largest randomized trials to date to explore the ef-
fects of HF dialysis, support the beneficial effect of minimally reused HF dialyzers while
suggesting a higher benefit for hypo-albuminemic patients and possibly for diabetics.
Our finding of a 25–30% relative risk reduction for patients dialyzed with minimally reused
HF dialyzers appears plausible as it is consistent with multiple sources of data. Specifically, our
numerical estimate is nearly equal to the effects of HF dialysis in MPO (in which reuse was not
permitted) and is also in line with existing observational studies [21] that were used in the de-
sign of HEMO [8,25] and MPO [36]. Furthermore, the reduction in all-cause mortality is driv-
en by reductions in cardiac and cardiovascular mortality. This pattern is consistent with
multiple non-randomized analyses of the outcomes of HF dialysis [3,5–7,38]. In addition, the
effects of HF dialysis appear larger in magnitude among hypo-albuminemic and diabetic pa-
tients in whom previous pre-specified RCT [10] and post-hoc [6] observational analyses have
Fig 5. Predicted Hazard Ratio (HR) of High Flux(HF) dialysis as a function of membrane reuse.
Predictions were obtained by fitting a meta-regression model to adjusted (for age, gender, diabetes, vascular
access and comorbidity score) HR of subgroups of HEMO (defined on the basis of reuse quartiles, Kt/V and
flux) and MPO. The meta-regression model accounted for Kt/V and the (square) of the extent of reuse. Of
note, reuse of HF membranes up to 13 times appears to yield a protective effect with a predicted RR of 0.83,
and an associated 95% CI: 0.70–0.99 that excludes unity.
doi:10.1371/journal.pone.0129575.g005
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respectively suggested a larger benefit. Lastly, our meta-analysis of HEMO and MPO, which ac-
counts for the differences in dialysis dose and reuse, shows a consistent benefit of non-reused
and minimally reused HF dialyzers effects on all-cause mortality. Our simulation analyses uti-
lizing the HEMO dataset predict that the adoption of HF dialysis in the US may have contrib-
uted to the 25% relative decline in mortality of the prevalent hemodialysis population seen
over the last 15 years [49].
A tacit assumption made by investigators considering the overall null results of HEMO
[10,50] is that reuse somehow render higher flux dialyzers less effective compared to their non-
reused counterparts. Our analysis of the HEMO data does find an association between reuse
and dialyzer flux, but in the opposite direction: rather than negatively affecting the survival of
patients dialyzing with reused HF membranes, reuse improved the outcomes of LF dialysis. To
our knowledge this is the first analysis to highlight the importance of the extent of reuse and
membrane flux in addition to membrane material and reprocessing technique [51] on out-
comes The existing literature includes harmful [51–54], protective [55] or null associations
[13,56] and an overall neutral effect on mortality across the various studies [57]. The conflict-
ing nature of the literature seems hardly surprising given the numerous factors that could con-
found the relation between reuse and outcomes. In particular, one could posit that reuse may
be affecting RRF, an underappreciated but powerful predictor of survival in hemodialysis
[24,26,27,58–60]. This hypothesis seems unlikely as an explanation for the associations we re-
ported in HEMO, since the study enrolled patients with minimal RRF (urea clearance<0.5 ml/
min) and most patients (67%) were anuric at baseline. Hence, an analysis of reuse on residual
diuresis over time is limited by the small number of study participants that simultaneously had
non-negligible urine output at baseline and follow up. Previous investigators have looked into
the question of changes in RRF and beta 2 microglobulin in HEMO [61] and concluded that
“rigorous modeling the rate of decline in residual kidney function is prohibited because the ma-
jority of patients had no measurable residual kidney clearance at baseline”.
To better understand the effects of HF dialysis on outcomes in the HEMO Study, we jointly
modeled survival and β2M concentration in study participants. This novel analysis suggests
that changes in β2M concentration explain one third of the estimated benefit of minimally re-
used HF dialyzers, while the remainder is accounted for by direct effects which are not related
to β2M. Thus, in spite of the theoretical predominance of the “middle molecule” hypothesis on
dialysis technology research[62], a closer examination of HEMO suggests that removal of these
uremic solutes may have only a modest effect on outcomes. Although β2M is considered a
marker for the entire spectrum of “middle”molecule toxins [63,64], other uremic retention sol-
utes may demonstrate dialytic kinetics that differ from those of β2M [65,66]. It is conceivable
that the direct flux effect, could be ascribed to an imprecise quantification of middle molecule
exposure by the predialysis β2M concentration, the removal of other molecules or to non-clear-
ance effects of dialyzers. Recent work by our group shows that the predialysis β2M concentra-
tion is an accurate measure of the time averaged concentration of β2M[67,68], so that the first
hypothesis appears unlikely. Although research to date has largely focused on β2M kinetics
[69] and its involvement in dialysis related amyloidosis, the knowledge gap in the field of ure-
mic toxicity does not rule out the possibility i.e. the direct effect of flux is HEMO is mediated
through the clearance of non-β2M “large” molecules. However, this appears a less likely expla-
nation since the clearance of these molecules by HF dialyzers is smaller than the clearance of
Fig 6. Meta-analysis of adjusted Hazard Ratio in HEMO study participants dialyzed with non-reused
HFmembranes and MPO patients. (A) all patients, (B) hypo-albuminemic patients, (C) patients
with diabetes.
doi:10.1371/journal.pone.0129575.g006
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urea and β2M which were both controlled by HEMO. Consequently, the possibility that reused
membranes exhibit differential kinetics of elimination is more theoretical than real. Even if dif-
ferential kinetics of large molecules was they play, the latter would have to exhibit an improba-
ble combination of high threshold for toxicity (otherwise patients would not survive long
enough to be enrolled in HEMO) and an extremely adverse toxicity profile after the threshold
(otherwise a differential effect would not be observed in HEMO). These considerations argue
that non-clearance attributes of dialyzers explain the direct effects of flux and its modification
by reuse.
An insight into the processes underlying the direct effects of flux and the effects of reuse
comes from our dynamic outcomes simulations in which reuse had a striking modulating effect
on LF but not on HF dialysis. Compared to non-reused LF membranes, reused ones were asso-
ciated with improved survival, while reusing HF dialyzers had essentially no impact on surviv-
al. As dialyzer reuse [70] is generally [71–73], but not invariably [74–76] associated with
enhanced biocompatibility and reduced oxidative stress, it would be tempting to speculate that
this discrepancy can be attributed to an improvement in biocompatibility seen only with reuse
of LF dialyzers. However, a selective increase in the biocompatibility of LF dialyzers by reuse
appears unlikely for a number of reasons. Firstly, bioincompatible membranes were prohibited
in HEMO [9,16] ruling out a difference in the ex-factory biocompatibility between HF and LF
dialyzers. Furthermore, had a selective reuse-related improvement in biocompatibility oc-
curred, one would expect this to be associated with reduced production rates of inflammatory
biomarkers (including β2M [73]) only with LF dialysis [71]. In a study, such as HEMO, of func-
tionally anephric patients in which middle molecule clearance is stably controlled by protocol,
higher rates of β2M production would be associated with progressive accumulation over time.
However reuse v.s non-reuse decreased the chronic slope in the β2M concentration to a similar
extent in the two study arms. Therefore, if biocompatibility was improved by reuse, it probably
did so to the same extent for LF and HF membranes. This conclusion is compatible with a pre-
vious report in a subgroup of patients from HEMO which showed that reuse improved phago-
cytic cell function (an index of membrane biocompatibility [77,78]) irrespective of membrane
flux [79]. Taken together these considerations suggest that reuse improved biocompatibility of
both LF and HF dialyzers in HEMO but additional factors have to be invoked to explain the
lack of outcome improvement with reuse of HF dialyzers.
Previous assessments of HF dialyzers [80–84] by morphometric (via Atomic Force and
Transmission Electron Microscopy), protein elution and immunoblotting methods have re-
vealed alterations in morphology (increased pore size, cracking) and protein deposition in the
dialysate side of the HF membranes associated with first use and subsequent reuses. These pro-
teins with a molecular weight< 30kDa correspond to middle molecules that had been filtered
in previous dialysis sessions with the same membrane and could (along with chemical residues
from the fractured membrane material) theoretically been back-filtered to the patient during
subsequent dialysis sessions. As such proteins are not filtered at all by LF membranes the com-
bination of previous deposition in the internal (dialysate side), enhanced permeability and
back filtration of previously filtered middle molecules could offer an attractive explanation of
the differential effects of reuse on outcomes with HF and LF membranes.
The use of HF dialyzers is now widespread worldwide [2] and will increase further as con-
vective therapies (hemodiafiltration/hemofiltration) that require these filters become estab-
lished through evidence from randomized trials [85–87]. Our analysis of reuse in HEMO and
the synthesis of HEMO and MPO have implications for nephrology practice. In the developed
world, where reuse of dialyzers is either prohibited by law (European Union and Japan) or not
practiced as a result of operational protocols (the majority of the dialysis providers in the
USA), we suggest that LF membranes should be abandoned in favor of HF dialyzers. To the
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extent that HF dialyzer reuse is a necessary component of a dialysis program for environmental
[57], financial (e.g. other dialysis providers in the USA) [88] or resource constraint (as in lower
income countries) [14,76,89,90] reasons, we believe that reused HF dialyzers may realize the
same benefits over non-reused LF dialyzers and thus HF membranes should also be preferred.
Though extensive reuse of LF dialyzers is unlikely to ever be practiced except in severely re-
source-constrained settings, our re-exploration of HEMO suggests that there may be upsides in
not adopting HF dialysis in these environments. Furthermore, in such systems substantial pro-
portion of dialysis units lack proper water treatment facilities [14,89] making the use of HF
membranes risky as a result of backfiltration [91,92], while the reduced (usually biweekly) dial-
ysis frequency limits the cumulative removal of middle molecules.
These findings should be interpreted in light of the following limitations. First, our analysis is
a secondary one, suitable for generating hypothesis for further studies. HEMOwas not designed
to test the effects of non-reused HF dialyzers, hence we cannot rule out the possibility of chance
underlying the beneficial effects of non-reused to slightly reused HF dialyzers. Nevertheless, a
large number of confounding factors, which could have conceivably affected outcomes assess-
ment (including baseline urine production), did not differ between the two flux arms within
reuse quartiles. Furthermore, a patient level meta-analysis between HEMO andMPO should be
undertaken to corroborate the impression that the flux effect appears to be larger in patients with
hypo-albuminemia and diabetes while examining the cardiovascular and infectious components
of mortality. Such an analysis could also consider the residual renal function and its evolution
over time in both studies in order to explore the combined dialytic/residual renal clearance on
outcomes. Second, the reason for the apparent attenuation in relative survival of patients dialyzed
with HF dialyzers cannot be discerned from this report. As this attenuation does not appear to be
related to β2M concentration or clearance, analyzing the HEMO samples in the NIDDK biobank
repository [93,94] could offer some insights about a putative biocompatibility benefit limited
only to LF membranes or the backfiltration hypothesis we endorse.
As the largest study of dialyzer flux in chronic hemodialysis patients, the HEMO Study find-
ings have strongly influenced patient care and are referenced by the US [95], UK Renal Associa-
tion [96], European Best Practice Guidelines on Hemodialysis Strategies [97], and the Australian
Hemodialysis Clinical Guidelines [98]. This work provides a more detailed examination of vari-
ability of outcomes related to dialyzer reuse in HEMO. Our analysis uncovers hitherto unrecog-
nized compatibilities in the findings of HEMO andMPO with respect to the overall effects of
non-reused HF dialyzers, but also in the clinically important subgroups of hypo-albuminemic
and diabetic patients. As these two studies contribute the bulk of RCT evidence for or against
higher permeability membranes, our analysis may allow for a more precise appraisal of the avail-
able body of data justifying the widespread use of HF dialyzers. Furthermore, this analysis rein-
forces the recent guideline updates [98,99] which endorse the use of HF membranes in clinical
practice. Future examination of longitudinal changes in biomarkers in previously established bio-
repositories and of physicochemical properties of membranes may be able to pinpoint the non-
clearance factors that explain the effects of dialyzer flux. Finally such an examination will suggest
novel ways to materialize technological innovations to further improve patient outcomes.
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